The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Lysosomal Biomarkers Program, 2023Investigating the Role of Lysosomal Biomarker ATP13A2 in the Pathogenesis of Parkinson’s Disease
Study Rationale: Lysosomal impairment is strongly implicated in the pathology of Parkinson’s disease (PD). Loss-of-function mutations in ATP13A2, a gene that encodes a lysosomal protein, are causally...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Analysis of the Lysosomal Lipid Metabolism Pathway and Other Pathways, Subgroups and Stages in Parkinson’s Disease
Study Rationale: Lysosomes are cellular compartments involved in clearing molecular debris. Several genes that work in the lysosome, including GBA1, GALC, SMPD1 and others, are known to be involved in...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting the Blood-brain Immune Axis to Prevent Progression of Parkinson’s Disease
Study Rationale: Recent studies suggest that the barrier that separates the brain from the rest of the body, including the blood, might become dysfunctional over the course of Parkinson’s disease (PD)...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023SUPPLEMENT | CMA as a Means to Counteract Alpha-synuclein Pathology in Non-human Primates”
Study Rationale: One of the main pathways to remove excess amounts of the alpha-synuclein protein that is linked to Parkinson’s disease (PD) is the lysosomal chaperone-mediated autophagy (CMA) pathway...
-
Lysosomal Biomarkers Program, 2023Validating Measurements of Peripheral GCase Longitudinally Under Clinical Trial Conditions
Study Rationale: An enzyme known as GCase is a key protein that stops working properly in people with Parkinson’s disease (PD). However, determining exactly how impaired the enzyme’s activity might...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Effect of SAR-CoV-2 on Experimental Parkinsonism in a Preclinical Model of Parkinson’s Disease
Study Rationale: Approximately 16.5 million people have been infected with the SARS-CoV2 virus. While primarily a respiratory virus, clinical observations indicate that in many cases, infection is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.